NeuroSense co-founder and CEO Alon Ben-Noon was inspired to find an effective treatment for ALS after meeting with ALS patient Shay Rishoni. Alon founded NeuroSense with years of experience running a consulting firm that collaborated with several leading pharmaceutical companies. He was joined by an outstanding team of ALS specialists, with women making up 75% of the company.

 

Alon’s team began their research by studying pre-existing FDA-approved molecules that could target the main pathological pathways of ALS. After extensive research, they concluded that 2 molecules, Ciprofloxacin and Celecoxib, could potentially work synergistically to inhibit the progression of ALS. NeuroSense was contacted by entrepreneur Alon Gordon, who was inspired to find a cure after his wife was diagnosed with ALS. Gordon offered to fund NeuroSense’s research in an Israeli laboratory that specializes in drug screening with an ALS model of zebrafish, which have over 70% genetic similarity to humans. Additionally, the striking resemblance between the brains, immune systems, and nervous systems of humans and zebrafish makes zebrafish an ideal research model for ALS.

 

Following outstanding preclinical results, NeuroSense filed a patent and gained an Orphan Drug Designation from the FDA. Clinical studies began in Israel and the United States to evaluate the efficacy, safety, and tolerability of PrimeC. Due to promising preliminary results, NeuroSense hopes to bring PrimeC to the market within 4 years and is currently running fundraising campaigns. NeuroSense also hopes to use PrimeC to battle Alzheimer’s and Parkinson’s.